Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Baricitinib has shown statistically significant improvements in clinical outcomes compared to placebo, achieving EASI 50 and EASI 75 at week 16. However, it has not been directly compared with dupilumab, and indirect comparisons suggest it may be less effective than dupilumab. The evidence indicates comparable efficacy to existing options but lacks a clear edge, justifying a B++ rating.
Cost effectiveness
The cost-effectiveness estimates for baricitinib are within acceptable thresholds for Healthcare resources, with ICERs suggesting it is likely cost-effective compared to both dupilumab and best supportive care. The committee concluded that baricitinib is a cost-effective use of Healthcare resources, supporting an A rating.
Quality of life
Baricitinib demonstrated statistically significant improvements in quality of life measures such as the DLQI and EQ-5D at week 16. Although the improvements are positive, the committee noted that the quality-of-life benefits may wane over time, leading to a moderate rating rather than a higher one.
Supporting Domains
Safety and Adverse Effects
Baricitinib has a generally favorable safety profile, with low rates of serious adverse events reported in clinical trials. Although some adverse events were noted, they were manageable, leading to a strong safety rating.
Comparator Selection
The committee recognized that while dupilumab and best supportive care are appropriate comparators, the indirect treatment comparison with systemic immunosuppressants was deemed unreliable due to differences in patient populations and outcomes. This leads to a B++ rating due to the need for substantial assumptions.
Patient Population and Subgroups
The trials included patients with moderate to severe atopic dermatitis, and the committee concluded that the populations in the trials were representative of those likely to receive baricitinib in clinical practice. However, there were concerns about the lack of data for patients with dark skin, which slightly limits the rating.
Care Pathway Integration
Baricitinib can be integrated into existing treatment pathways with minor adjustments, as it is positioned as a fifth-line treatment after systemic immunosuppressants. The committee noted that it would require some planning but is manageable, justifying an A+ rating.
Resource Use and Cost Implications
The budget impact of baricitinib is manageable, and while it may incur notable costs, these are justified by the benefits it provides. The committee concluded that the resource implications are acceptable, supporting an A rating.
Evidence Quality and Robustness
The evidence base includes multiple randomized controlled trials with low bias risk. However, the lack of direct comparisons with dupilumab introduces some uncertainty, leading to an A rating rather than higher.
Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and quality-of-life benefits of baricitinib, particularly in relation to best supportive care. The committee acknowledged these uncertainties, leading to a B+ rating.
